Cynosure Group LLC Has $2.43 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Cynosure Group LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 1,028.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 36,232 shares of the medical device company’s stock after purchasing an additional 33,022 shares during the period. Cynosure Group LLC’s holdings in DexCom were worth $2,429,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Capital Insight Partners LLC grew its position in shares of DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after buying an additional 90 shares during the period. HM Payson & Co. increased its holdings in DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after purchasing an additional 100 shares in the last quarter. Clear Creek Financial Management LLC raised its stake in shares of DexCom by 4.2% in the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after purchasing an additional 120 shares during the last quarter. SeaCrest Wealth Management LLC lifted its holdings in shares of DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock valued at $501,000 after purchasing an additional 152 shares in the last quarter. Finally, Securian Asset Management Inc. raised its holdings in shares of DexCom by 0.7% in the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock valued at $2,593,000 after purchasing an additional 161 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Up 0.1 %

Shares of NASDAQ DXCM opened at $77.94 on Wednesday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business has a 50-day moving average of $70.94 and a 200-day moving average of $88.58. The firm has a market capitalization of $30.44 billion, a price-to-earnings ratio of 46.67, a PEG ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock worth $399,319 over the last three months. 0.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on DXCM shares. Piper Sandler restated an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. Sanford C. Bernstein lifted their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Stifel Nicolaus raised their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Royal Bank of Canada cut their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Wells Fargo & Company upped their price target on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.